Time limited offer for new users ▶ Get up to 3 months free

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Harvard Business School

Last Updated: February 4, 2023

Details for Patent: 8,048,035

✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions

Summary for Patent: 8,048,035
Title:Automatic injector with needle cover
Abstract: An auto-injector automatically dispenses a predetermined dose of medicament upon activation. The auto-injector includes a needle cover operative to engage an injection site and activate the injector. The needle cover is configured to move from a locked retracted position prior to a medicament dispensing operation to a locked extended position after the medicament dispensing operation. The non-removable needle cover prevents contact with the needle both before and after the medicament dispensing operation.
Inventor(s): Mesa; C. Michael (Boyds, MD), Cors; Sarah Jane (Reston, VA), Penney; Melinda Fischer (Providence, RI), Tomellini; Dalita Rosemarie (Rehoboth, MA), Bremley; Mark Bumb (Edwardsville, IL), Wilmot; John Glyndwr (Mount Airy, MD), Young; Matthew Egerton (Over Cambs, GB), Raven; Sophie Rebecca (Swavesey Cambs, GB), Murphy; Martin Joseph (Letchworth Garden City Hearts, GB), Hurlstone; Christopher John (Newport Saffron Walden Essex, GB), Daintrey; Joseph William (Royston Herts, GB), Rochford; Craig Malcolm (Monxton Andover Hants, GB), Kirkwood; Stephen Philip (Haynes Beds, GB), Mathews; Colin James (Godmanchester Huntingdon, GB), Hill; Robert L. (Abingdon, MD)
Assignee: Meridian Medical Technologies, Inc. (Columbia, MD)
Application Number:12/258,754
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 8,048,035
Patent Claim Types:
see list of patent claims
Use; Dosage form;

Drugs Protected by US Patent 8,048,035

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Mylan Speciality Lp EPIPEN epinephrine INJECTABLE;INTRAMUSCULAR, SUBCUTANEOUS 019430-001 Dec 22, 1987 AB RX Yes Yes See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
Mylan Speciality Lp EPIPEN JR. epinephrine INJECTABLE;INTRAMUSCULAR, SUBCUTANEOUS 019430-002 Dec 22, 1987 AB RX Yes Yes See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 8,048,035

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 2005271355 See Plans and Pricing
Australia 2010201665 See Plans and Pricing
Australia 2013222015 See Plans and Pricing
Canada 2576776 See Plans and Pricing
Canada 2683253 See Plans and Pricing
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:


Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.